Dr. Yajing Wang's research lab at the University of Alabama at Birmingham focuses on improving treatments for patients suffering from diabetic ischemic heart failure. By studying the role of specific cardiac proteins and cell therapies, the lab aims to engineer small extracellular vesicles that enhance heart protection in diabetic conditions. Their goal is to restore the heart's function by modifying the local microenvironment with advanced biomaterials.

Dr. Jianbo Wang's lab at the University of Alabama at Birmingham focuses on understanding how a specific signaling molecule, Wnt5a, contributes to skeletal development and its associated disorders. They explore the molecular mechanisms of skeletal formation, particularly how mutations in the WNT5A gene lead to congenital skeletal diseases like Robinow syndrome. The lab uses various biochemical and genetic techniques to develop insights that could ultimately aid in regenerative medicine and therapies for skeletal disorders.

Dr. Bradley K. Yoder's research lab focuses on understanding the role of cilia and their associated proteins in kidney health and disease. Their work investigates how mutations in certain genes cause kidney cysts and how these cysts are influenced by injury and cellular repair processes. By using mouse models, the lab aims to uncover the mechanisms behind cyst formation and identify potential therapeutic strategies to better manage polycystic kidney disease (PKD).

Dr. Jarred W. Younger's lab at the University of Alabama at Birmingham is focused on exploring treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating condition affecting many individuals. The lab is currently conducting a clinical trial on low-dose naltrexone (LDN), which is thought to reduce inflammation in the brain and improve symptoms associated with ME/CFS. Through a remote trial design, they aim to make participation accessible to individuals with severe symptoms and gather important data for future studies.